Abstract
Many advances have been achieved during the last decade in the field of lung cancer molecular biology, leading to the identification of potential new oncogene drivers and new therapeutic targets. However, only two targetable biomarkers are currently approved for lung cancer treatment: EGFR activating mutations and EML4-ALK rearrangements. Adenocarcinoma is the most common type of non-small cell lung cancer and was the first to be studied. Indeed, most of lung adenocarcinoma biomarkers were identified several years ago. Nevertheless, new therapies targeting these biomarkers are still investigated. More recently, new oncogene drivers have been identified in the field of lung squamous cell carcinoma and small cell lung cancer, and new agents are being developed to target these biomarkers.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
